Oct 17 (Reuters) – Johnson & Johnson (JNJ.N) on Tuesday said it has embarked on a two-year restructuring program for its orthopedic business after third-quarter medical devices sales fell short of Wall Street expectations, reflecting the company’s narrowed focus since spinning off its consumer health unit.
J&J said it plans to exit certain markets and stop selling some products under its orthopedic business as part of the restructuring program.
Without its consumer health business and medical devices undergoing restructuring, pressure on J&J’s large pharmaceutical unit is likely to intensify as the company aims to reach its goal of $57 billion in drug sales by 2025. Th…
Read the full article at: https://www.reuters.com/business/healthcare-pharmaceuticals/jj-raises-annual-profit-forecast-strong-cancer-drug-demand-2023-10-17/